MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
MacroGenics director Scott Koenig reported an RSU conversion into common stock. On February 15, 2026, he exercised restricted stock units and acquired 21,165 shares of MacroGenics common stock at a stated price of $0 per share, increasing his directly held position to 867,240 shares.
The RSUs were part of a 127,000-unit grant awarded on February 15, 2023. According to the disclosure, 84,670 units had vested before his separation from the company, and 21,165 additional units vested on August 13, 2025 under his Separation Agreement, with each RSU representing one share of common stock.
Frazier Life Sciences-affiliated funds and individuals have filed an amended Schedule 13G reporting no beneficial ownership of MacroGenics, Inc. common stock as of December 31, 2025. Each reporting person lists 0 shares beneficially owned and a 0.0% stake in the company’s common stock.
The filing covers multiple Frazier Life Sciences partnerships and LLCs, as well as James N. Topper and Patrick J. Heron, all organized in Delaware or the United States. They certify that any securities referenced were not acquired or held to change or influence control of MacroGenics, but rather on a passive basis.
MacroGenics director Scott Koenig converted 15,831 restricted stock units into an equal number of MacroGenics common shares on February 8, 2026, at an exercise price of $0 per share. After this conversion, he directly owned 846,075 shares of common stock and 15,832 RSUs.
The RSUs come from a 95,000-unit grant on February 8, 2024. One-third vested after one year, and half of the remaining units vested under a Separation Agreement on August 13, 2025. The rest vest in two equal annual installments on the grant anniversary.
MacroGenics, Inc. senior vice president Thomas Spitznagel reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,001 and 8,999 shares of common stock, respectively, on a one-for-one basis. On each date, 2,485 and 3,186 shares were withheld at $1.81 per share to cover taxes. After these transactions, Spitznagel directly owned 30,731 shares of MacroGenics common stock.
MacroGenics VP, Controller & Treasurer Beth Ann Smith reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On February 7, 2026, 2,617 RSUs converted into 2,617 shares of common stock at an exercise price of $0, with 1,011 shares of common stock withheld at $1.81 per share, leaving 11,138 shares directly owned afterward. On February 8, 2026, a further 1,583 RSUs converted into 1,583 shares of common stock at $0, with 612 shares withheld at $1.81 per share, resulting in 12,109 common shares directly owned. RSUs convert into company stock on a one-for-one basis, and remaining RSU balances after these transactions were 5,233 and 1,584 units for the two respective grants.
MacroGenics (MGNX) President and CEO Eric Blasius Risser reported multiple equity award transactions in early February 2026. On February 7, 2026, 6,668 restricted stock units (RSUs) converted on a one-for-one basis into common stock, increasing his direct holdings to 62,657 shares before a 2,575-share disposition at $1.81 per share, leaving 60,082 shares.
On February 8, 2026, a further 11,166 RSUs converted into common stock, taking his direct common stock position to 71,248 shares before a 4,311-share disposition at $1.81 per share, resulting in 66,937 common shares directly owned. Following these transactions, he held 13,332 RSUs from a February 7, 2025 grant of 20,000 units and 11,166 RSUs from a February 8, 2024 grant of 33,500 units, each vesting in three equal annual installments.
MacroGenics, Inc. insider activity: Senior VP, General Counsel and Secretary Jeffrey Stuart Peters reported routine equity compensation events. On February 7 and 8, 2026, portions of previously granted restricted stock units vested and were converted into common stock on a one-for-one basis.
On those dates, a total of 6,001 and 8,999 common shares, respectively, were acquired upon RSU conversion at an exercise price of $0. In connection with these vestings, 2,317 and 3,474 shares of common stock were withheld at $1.81 per share to satisfy tax obligations, coded as transaction type “F.”
Following the reported transactions, Peters directly held 22,920 shares of MacroGenics common stock. He also continued to hold derivative positions in restricted stock units from earlier grants, which were originally 18,000 units granted on February 7, 2025 and 27,000 units granted on February 8, 2024, each vesting in three equal annual installments.
MacroGenics SVP and CFO James Karrels reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,334 and 9,999 shares of common stock, respectively, on a one-for-one basis. In connection with these vestings, 2,446 and 3,860 shares of common stock were withheld at $1.81 per share to cover tax obligations.
After these transactions, Karrels beneficially owned 196,828 shares of MacroGenics common stock, held directly and jointly with his wife, plus 12,666 and 9,999 remaining restricted stock units from prior grants that continue to vest over time.
MacroGenics Inc. insider activity: Sr VP, Research & CSO Ezio Bonvini reported routine equity transactions on February 7 and 8, 2026 involving restricted stock units (RSUs) and common stock of MacroGenics Inc. (MGNX).
On February 7, RSUs converting on a one-for-one basis were exercised for 7,001 shares of common stock, increasing his directly held common stock to 131,415 shares, while 2,703 shares were withheld at a price of $1.81 per share, leaving 128,712 shares directly owned. On February 8, an additional 11,166 RSUs were exercised into common stock, bringing direct common stock holdings to 139,878 shares before 4,311 shares were withheld at $1.81 per share, resulting in 135,567 directly owned common shares.
Following these transactions, Bonvini also held 13,999 RSUs from a February 7, 2025 grant of 21,000 RSUs vesting in three equal installments and 11,166 RSUs from a February 8, 2024 grant of 33,500 RSUs, also vesting in three equal installments beginning on the first anniversary of each grant date.
MacroGenics, Inc. announced that Stephen Eck, M.D., Ph.D., its Senior Vice President, Clinical Development and Chief Medical Officer, will depart the company effective December 31, 2025, following a mutual agreement reached on November 14, 2025. Oversight of clinical development will be handled on an interim basis by Frank Perabo, M.D., Ph.D., Vice President, Clinical Development, while an executive recruiter conducts a search for a new Chief Medical Officer. Dr. Eck, who joined MacroGenics in July 2020 and led clinical development across multiple studies, will receive payments and benefits for a qualifying termination in accordance with his employment agreement, conditioned on a general release, waiver of claims, and compliance with his restrictive covenants.